Eptinezumab-jjmr (Vyepti)

Vyepti (eptinezumab‑jjmr) is covered for prevention of migraine in adults ≥18 years with ≥4 migraine days/month and is not covered for patients <18 or with <4 migraine days/month. Approval (up to 300 mg IV every 3 months, initial and renewals limited to 1 year) requires documented diagnosis and baseline frequency, prior trials of at least two prophylactic agents from different classes with inadequate efficacy or intolerable adverse events, trial of at least one triptan or a documented contraindication to triptans, planned dosing, and any applicable safety documentation.

"Prevention of migraine headaches in adults"

Sign up to see full coverage criteria, indications, and limitations.